Stemline Therapeutics

Stemline Therapeutics is a biopharmaceutical company focused on the development and commercialization of oncology therapeutics. The company describes its goal as building a leading biopharmaceutical business that improves the lives of people with cancer through novel, first-in-class treatments. Its website identifies Stemline as part of the Menarini Group, an international pharmaceutical and diagnostics company. Stemline’s featured marketed medicines include ELZONRIS (tagraxofusp-erzs) and ORSERDU (elacestrant). ELZONRIS is a targeted therapy directed to CD123 and is approved in the United States for adults and pediatric patients aged two years and older with blastic plasmacytoid dendritic cell neoplasm (BPDCN). The company reports that the European Medicines Agency approved ELZONRIS in January 2021. Stemline also states that the medicine is being evaluated in clinical trials for additional indications, including acute myeloid leukemia, chronic myelomonocytic leukemia, and myelofibrosis. ORSERDU is a selective estrogen receptor degrader approved in the United States for postmenopausal women or adult men with estrogen receptor-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer following at least one line of endocrine therapy. Stemline describes its wider work as developing a broad oncology pipeline and says it is open to in-licensing, co-development, and acquisition opportunities to expand that pipeline. Its website identifies Ivan Bergstein, MD, as founder, CEO, and president.

Stemline Therapeutics was founded by Ivan Bergstein, MD, who is identified on the company’s management page as its founder and as CEO and president. The supplied company materials do not specify a founding year. The company describes its purpose as developing and commercializing novel, first-in-class oncology therapeutics, with a focus on improving the lives of people with cancer. Stemline’s development and commercial activities include ELZONRIS (tagraxofusp), a targeted therapy directed to CD123. The company reports that ELZONRIS received U.S. FDA approval for adults and pediatric patients aged two years and older with BPDCN and that it is commercially available in the United States. Stemline also states that the European Medicines Agency approved ELZONRIS in January 2021. The company reports ongoing clinical evaluation of the therapy in other indications, including acute myeloid leukemia, chronic myelomonocytic leukemia, and myelofibrosis. The company’s other highlighted medicine is ORSERDU (elacestrant), a selective estrogen receptor degrader. Stemline describes it as FDA-approved for certain adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer following at least one line of endocrine therapy. The company points to results from the pivotal EMERALD trial and describes potential further study of the compound alone or in combination with other therapies. Stemline’s current company materials identify it as part of the Menarini Group. Its stated development strategy includes building a broad oncology pipeline and using its drug development, manufacturing, and commercialization expertise. The company invites potential partners to propose in-licensing, co-development, or acquisition opportunities. Its management page says Mr. Hoberman has served as chief operating officer since 2013. The supplied materials do not provide a complete corporate chronology or a founding date.

• 2021

  European Medicines Agency approves ELZONRIS

• 2013

  Mr. Hoberman begins serving as Chief Operating Officer

An oncology-focused biopharmaceutical company developing and commercializing novel therapies, including first-in-class treatments, as part of the Menarini Group.

• ELZONRIS (tagraxofusp-erzs)

  A CD123-directed therapy approved in the United States for BPDCN in adults and pediatric patients aged two years and older; the company reports European approval in January 2021.

• ORSERDU (elacestrant)

  A selective estrogen receptor degrader approved in the United States for specified adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer following at least one line of endocrine therapy.

1. 1Home - Stemline Therapeuticsstemline.com
2. 2About Us - Stemline Therapeuticsstemline.com
3. 3Management - Stemline Therapeuticsstemline.com
4. 4Business Development - Stemline Therapeuticsstemline.com
5. 5Stemline Therapeutics (United States)wikidata.org